Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
HORA-RPE65(Horama SA) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
HORA-RPE65(Horama SA): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Norovirus vaccine (Yidao biotechnology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Norovirus vaccine (Yidao biotechnology): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
T-01 (Treamid) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
T-01 (Treamid): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CT-101(CarMell Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
CT-101(CarMell Therapeutics): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Acute Urinary Retention(Antev) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Acute Urinary Retention(Antev): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BRS-201(Brigham and Women's Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
BRS-201(Brigham and Women's Hospital): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AR-100(Rejenevie) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
AR-100(Rejenevie): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PEP-001(Pepper Bio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
PEP-001(Pepper Bio): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EB-109(Eluminex Biosciences) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
EB-109(Eluminex Biosciences): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
E7 TCR-T cell therapy(CINJ) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
E7 TCR-T cell therapy(CINJ): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SP-20104(1 A Pharma GmbH) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
SP-20104(1 A Pharma GmbH): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PCSK9 siRNA(Jiangsu Hengrui ) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
PCSK9 siRNA(Jiangsu Hengrui ): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.